NuVision Biotherapies

The company's core business revolves around the commercialization of biotherapies for treating 'front of the eye' diseases and trauma. Its main product, Omnigen®, is a wound dressing and grafting material derived from amniotic membrane, the sac that surrounds a baby in the womb. This natural biomaterial is used to support healing, minimize inflammation, and reduce pain on the ocular surface. Unlike traditional applications that required surgery and sutures, Omnigen, when combined with NuVision's specially designed bandage contact lens, OmniLenz®, can be applied in a simple, non-surgical procedure in an outpatient setting. This innovation makes amniotic membrane treatment more accessible to a wider range of patients at an earlier stage of their condition.

NuVision serves ophthalmologists, optometrists, and hospitals, with its products being used in over 160 UK hospitals for conditions resulting from traumatic injury, eye surgery, and chronic diseases. The company is expanding globally, with partnerships to distribute its products in countries including the Netherlands. Its business model appears to be based on the sale of its Omnigen and OmniLenz products to healthcare providers and institutions. The company has received funding from investors such as Mercia Asset Management, Pioneer Group, and the Midlands Engine Investment Fund.